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ABSTRACT

The main goal of this study is to develop a floating tablet of famotidine using hot melt extrusion
coupled (HME) with Fused deposition modeling FDM 3D printing technology. Seventeen
different formulations were prepared to obtain printable HME filaments. Hydroxypropyl
cellulose (HPL-LF), hydroxypropyl cellulose (HPLC-EF), Hydroxypropyl Methylcellulose
(HPMC-E5), and Ethyl Cellulose (EC) were used as polymeric carriers with 10% (w/w)
famotidine. Polyethylene Glycol 1500 (PEG-1500) was used as a plasticizer. The resulting
physical mixtures were then extruded using an 11 mm twin-screw co-rotating extruder (Thermo
Fisher Scientific, Waltham, MA, USA). The HME filaments were then printed using an FDM3D printer (Prusa i3 3D desktop printer, Prusa Research, Prague, Czech Republic) with a
thickness of 0.4mm, line pattern, and 100% infill at 180 °C printing temperature.
Famotidine, polymeric carriers, other excipient, filaments, and 3D printed tablets were analyzed
to determine the physical state of famotidine by using a Differential Scanning Calorimetry
(DSC). The in-vitro drug release profile of the printed tablets was evaluated. Five filaments
(M10, M11, M15, M16, M17) out of seventeen were successfully printable. The tablets were
printed in a line pattern and 100% infill with a hollow shape to have a low-density tablet that
may reach the target of floating on the surface of the stomach for a more extended time.
The famotidine DSC thermograms showed an endothermic melting peak at 163.5 °C. This
endothermic peak disappeared in the extruded filament and the 3D-printed tablets. The
ii

disappeared peak indicates complete solubilization of famotidine in the polymeric carrier for all
Five formulations.
Drug content tests were performed from the best-printed tablets for M10, M11, and M17. The
accepted formulations for further investigation were M10 and M17, respectively, which showed
a release for 9 hours and 8 hours. The floating profile for M10, M11, and M17 was successful for
around 8 hours.
HME revealed the great potential to develop suitable filaments for FDM-3D printing. The
formulation compositions and printing design and pattern are the keys to developing 3D printed
floating tablets for famotidine.
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CHAPTER I
INTRODUCTION
Three-dimensional (3D) printing is an advanced technology that involves the layer-by-layer
deposition of materials to create a final desired product [1]. 3D printing is a highly revolutionary
technology within the pharmaceutical area. Since 3D printed drug was first approved by the US
Food and Drug Administration (FDA) Spiritam in 2015, research in 3D printing for drug
manufacturing has been expanding. The overall 3D printing types are illustrated in figure 1. 3D
printing is considered as an additive manufacturing technology which is used for fabricating parts
layer-by-layer directly from a computer-aided design (CAD) data file.

3D printing
types

Vat
Polymerizai
on
(photopoly
merization)
SLA
DLP

Powder
Bed Fusion
(Polymers)
-SLS

Poweder
Bed Fusion
(metals)
-DMLS
-SLM
-EBM

FDM

Figure 1: Different 3D printing types.

1

Matterial
Jetting

Binder
Jetting

-Material
jetting
DOD

-Binder
Jetting

Stereolithography (SLA) is an industrial 3D printing procedure known as the most common resin 3D
printing process. It is used to create concept models, cosmetic prototypes, and complex parts with
sophisticated geometries in a brief period [2]. Selective Laser Sintering (SLS) is a subcategory of
powder bed fusion 3D printing; it uses a laser beam to create solid items by heating power particles
and fusing them at their surfaces.[3]. Inkjet printing is like other 3D printing methods, which continues
through layer-by-layer deposition by using low temperature and low pressure to depose liquid
materials or solid suspensions[4].
Fused Deposition Modeling (FDM) 3D printing is our research objective type with Hot
Melt Extrusion (HME). FDM 3D printing is overall compatible with printing drug products and
polymer filaments as materials for drug carriers [5],[6].FDM implies building objects by adding
material in a layer-by-layer fashion to create a 3D part, benefiting from generating any design. It
provides efficient models in various thermoplastics due to its ability to produce complex
geometrical sections nearly and safely in an office-friendly or lab environment[7].
The importance of 3D printing lies in producing small batches of medications with
specific dosages, shapes, sizes, and release profiles. The production of drugs using 3D printing may
finally lead to the model of personalized medicines becoming a promising target [8].
Hot-Melt Extrusion (HME) began as a novel processing technology in developing solid
dispersions of active pharmaceutical ingredients (APIs) into a various polymer or/and lipid
matrices [8] Several published reports on the different HME applications in the pharmaceutical area
involve solid dispersions, targeted drug delivery systems, sustained-release formulation, films,
microencapsulation, nanotechnology, floating drug delivery systems, taste masking, and implants.[9]
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Hot Melt Extrusion (HME) is one of the industry's most extensively used processing
procedures. It is pumping raw materials with a screw under high temperature and pressure
through a heated barrel into a uniform shape and density product. The HME usually consists of
one or two screws inside a stationary cylindrical barrel, either co-rotating or counter-rotating.
Regardless of the type and complex process, the HME must rotate the screw at a pre-determined
speed while balancing the torque and shear produced from both the extruded material and the
screw configuration.
A standard HME setup consists of a motor that acts as a drive unit, an extrusion barrel, a
rotating screw, and an extrusion die. A central electronic control unit is connected to the
extrusion to monitor and control the parameters such as screw speed, temperature, and pressure
(figure 2).

Figure2. Schematic diagram of Hot Melt Extruder.
The extrudates' physicochemical and mechanical characteristics are influenced by
temperature, the thermal stability of materials, feeding rate, screw speed, the viscosity of
materials, shear rate, and elasticity of materials [9].
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The thermoplastic materials used in FDM 3D printers need to be in the form of a
filament. However, most filaments available are not suitable for pharmaceutical
applications[10]. Aside from this issue, most traditional polymer/ excipients used in
pharmaceutics do not have the appropriate thermal and mechanical properties that can be used to
make filaments needed for FDM 3D printing[11]. Some of the most common grades of
pharmaceutical polymers which can be prepared into filaments are Polyvinylpyrrolidone (PVP),
Polyvinyl alcohol (PVA), and Polylactic acid (PLA)[12]. These are suitable for their excellent
mechanical and thermal properties and have been used to extrude drugs to yield filaments that
can be used in an FDM 3D printer to create different dosage forms.
Conjugating HME and FDM 3D printing are viable for fabricating medicines based on
patient needs[13]. These two technologies can rationalize the complex processes of conventional
manufacturing methods to develop pharmaceutical products. Thus, there has been some
investigation into combining these two technologies into one continuous process to achieve a
more valuable and efficient manufacturing procedure. The coupling of HME with FDM 3D
printing into one single process opens up the possibility of creating any dosage forms in a
pharmacy/hospital for immediate use. Blending these two processes makes the fabrication of
dosage forms more cost-effective, efficient, and economical.[10]
Famotidine (Figure 3) is a competitive histamine H-receptor antagonist (H2RA) that
binds to the H-receptors located on the basolateral membrane of the parietal cell in the stomach,
effectively blocking histamine action. Famotidine is used to treat acid-related gastrointestinal
conditions, and the pharmacological activity developed by inhibiting gastric secretion by
suppressing acid concentration and volume of gastric secretion. [14]– [16]
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Figure 3. Famotidine chemical structure
Famotidine is (3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl] methylsulfanyl]-N'sulfamoylpropanimidamide), has a molecular weight of 337.5 g/mol, a crystal with a white to an
off-white color. The melting point is 163.5ºC[17]. Solubility at 20 °C 800 mg/mL in DMF; 500
mg/mL in acetic acid; 3mg/mL in methanol; 1mg/mL in water; <0.1mg/mL in ethanol, ethyl
acetate, and chloroform.[18]
After the oral administration of famotidine tablets, the absorption is dose-dependent and
incomplete. The oral bioavailability varies from 40 to 50%, and the Cmax is reached in 1-4 hours
post-dosing. The elimination half-life is about 2 to 4 hours [19]–[21].
Famotidine dosage forms are available both over-the-counter (OTC) and prescription (Rx). The
US FDA approved treating duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease
(GERD) [22] Dosage forms and strengths of famotidine available in US market for adults are
illustrated in table 1[23].
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Table1. List of dosage forms and strengths of famotidine in the US markets for adult use.
Dosage From

Prescribed / OTC

Strength

Injection Solution

Prescribed

10 mg/ml
0.4 mg/ml

Oral Suspension

Prescribed

40 mg/ml
10mg

Tablet

OTC

20mg
40 mg

Tablet (chewable)

OTC

10 mg
20 mg

The oral route is the predominant and most desirable route for drug delivery, although
drug absorption is sometimes incomplete and variable between individuals regardless of
excellent in vitro release patterns[24], [25]. The major problem in the oral dosage form is the
variation because of gastrointestinal transit and gastric retention time (GRT). These attributes
lead to developing a drug delivery system that will stay in the stomach for a prolonged and
predictable time.
One of the possible approaches is to control GRT using a gastroretentive dosage form
(GRDF) that will provide new and essential therapeutic options. GRDF can be retained in the
stomach and improve the sustained oral delivery of drugs that have an absorption window in
specific areas of the gastrointestinal tract. These systems help release the drug continuously
before it reaches the absorption window, ensuring optimal bioavailability[26].
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Floating drug delivery systems (FDDS) is one of the GRDF types, which was described
by Davis in 1968 [27]as a low-density system with enough buoyancy to float over the gastric
area and remain in the stomach for a sustained period. As the system floats over the gastric
contents, the drug is released slowly at the desired rate, which results in increased gastroretention time and reduces fluctuations in absorption. The advantages of FDDS are many, which
makes it a unique drug delivery system for various illnesses.
FDDS used to enhance the bioavailability of some drugs, sustain drug delivery, reduce
the frequency of dosing, target therapy for local effects in the upper GIT, minimize the
fluctuation of drug concentration, minimize adverse mechanism of action in the colon. Finally,
FDDS are considered site-specific systems. [28]
Further, FDDS is the most practical approach to prolonging the gastric retention time of a
dosage form [14] .Recently, FDM 3D printing has been utilized to fabricate floating aid devices [30],
floating pulsatile tablets [31], and floating control release matrixes[32][33]
HME coupled with 3D printing technology has been used to manufacture floating tablets.
X. Chai et al. studied in 2017 the Domperidone intragastric floating tablets for sustained release.
Domperidone is a dopamine (D2) receptor antagonist used in treating gastroparesis. X. Chai. Et
al. prepared cylinder-shaped tablets with different infill percentages and shell numbers to
investigate the floating capability of their tablet. They concluded that the buoyancy of the hollow
structure of tablets was directly related to their densities [34]
In another study, Vo A et al. investigated cinnarizine using HME FDM 3D printing to
develop HPC-based floating tablets. They observed an improvement in the physical properties of
the filaments and printing process when using VA-64 Kollidon® as a co-matric-forming
polymer. [35]
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The concept of famotidine floating tablets was introduced in 2007 by M. Jaimini et al.,
using an effervescent technique using different grades of Methocel (HPMC) based on viscosity.
Sodium bicarbonate was combined as a gas-generating agent. Citric acid’s effect on famotidine
drug release profile and floating properties was studied. The in vitro buoyancy study noted that
the tablet persisted buoyant for 6-10 hours Methocel K 100 was observed to float for a longer
duration than formulations Ethocel 15M [36]

The current research aims to develop a floating tablet of famotidine using HME coupled
with FDM 3D printing. To accomplish this target, polymeric carriers were selected (HPC with
different grades, PEO N80, HPMC E5, EC), Other excipients (PEG 1500) were screened to
operate printable hot-melt extruded filaments with 10% w/w famotidine.
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CHAPTER II
MATERIALS AND METHODS

2.1 Materials
Famotidine was purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Hydroxypropyl cellulose (HPC-LF) and hydroxypropyl cellulose (HPC-EF) were gifted from
Ashland Inc. (Wilmington, Delaware, USA). Polyethylene glycol (PEG 1500) was gifted from
Thermo Fisher Scientific (Waltham, MA, USA). Hydroxypropyl Methylcellulose (HPMC-E5)
was gifted from DOW (The DOW chemical company, Midland, Michigan, USA). Ethylcellulose
(EC) N.F. Premium was purchased from DOW (The DOW chemical company, Midland,
Michigan, USA). Polyethylene oxide (PEO N80) was gifted from Colorcon (Ruth Road
Harleysville, PA, USA). PLA filaments and all other chemicals and solvents were of analytical
grade and purchased from Fisher Scientific (Hanover Park, IL, USA).

2.2 Methods
2.2.1 Formulation compositions
As listed in Table 2, formulations were set to achieve printable filaments. HPC-LF, HPCEF, HPMC-E5, and EC were used as polymeric carriers. PEG-1500 was used as a plasticizer.
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Table 2. Famotidine formulations compositions
Formulatio
n code

M1
M2
M3
M4
M5
M6
M7
M8
M9
M10
M11
M12
M13
M14
M15
M16
M17

Famotidin
e
( % w/w)

klucel
™
HPCEF
(%
w/w)
94.1%
73.5%
70.6%

klucel
™
HPCLF
(%
w/w)

5.9%
5.4%
5.9%
100%
90%
85%

10%
10%
10%
10%
10%
10%
10%

Polyethylen
e glycol™
PEG 1500
(% w/w)

62.5%
80%
70%
60%
55%
75%
65%

10%

Methoce
l E5®
HPMCE5
(% w/w)

Ethocel
®
EC
(% w/w)

Polyo
x™
PEO
N80
(%
w/w)

21.1%
23.5%
10%

10%
5%

5%
22.5%
10%
20%
30%
30%
10%
20%
50%
33%
67%
60%

5%
5%
5%
50%
67%
33%
30%

2.2.2 Hot-Melt extrusion
Famotidine (10 % w/w), HPC, HPMC-E5, PEO N80, and EC, and PEG excipient of each
formulation (18-40 g) were blended homogenously using a V-Shell blender (Globalpharma,
Maxi blend, New Brunswick, NJ) for 10 minutes at 25 rpm. Then the resulting blends were fed
into an 11 mm co-rotating, twin-screw extruder (Thermo Fisher Scientific, Waltham, MA, USA)
with a 1.5 mm round die to achieve the desired 3D printing filament diameter. The extrusion
temperature was set at 115-160 ° C except for the first zone at which the temperature was set at
90 °C. The feeding rate was 2-3 g/min. The screw speed was set at 100 rpm.
2.2.3 Fused deposition modeling (FDM) 3D printing
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The floating tablet design was created using the TINKERCAD 3D modeling program.
The desired design was saved as stl. File and then, Cura© software from Ultimaker (Utrecht,
Netherlands) was utilized to link the designed floating tablets to the 3D printer (figure 4) and
operate all the printing settings. The First 3D printing attempt used PLA as a standard filament
with a 1.75 mm diameter to examine the 3D printed design and floating profile. The 3D printing
parameters for the tablets were maintained among all the formulations, as shown in table 3.

Bottom layer

(a)

(b)

(c)

Figure 4. The floating tablet design (a: software cylinder design, b: 3D shape hollow cylinder
design with bottom layer attached, c: top layer)
Table 3. Printing setting for the successful formulations.
Parameter

Values

Thickness (mm)

Course 0.4

Outer Wall linewidth (mm)

0.4
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Infill line width (mm)

0.4

Wall thickness (mm)

0.8

Wall line count

2

Infill Density (%)

100

Infill Pattern

Line

Printing Temperature (°C)

180

Build Plate Temperature(°C)

60

Printing Speed (mm/s)

60

2.2.4 Weight variation
Five 3D printed tablets were weighed using an analytical balance, and the average weight and
relative standard deviation were recorded.
2.2.5 Differential scanning calorimetry (DSC)
Famotidine, polymers, excipients, and physical mixtures of some formulations using a DSC
system (TA Instruments, New Castle, DE, USA) to examine the drug's physical state and determine
the drug-polymer miscibility. A 3-5 mg sample was weighted in an aluminum T-zero pan scaled
using a T-zero lid and then installed into the DSC beside a reference empty pan. The samples were
heated from 25 to 200 °C at a rate of 10 °C. TA Instruments TRIOS software was used to analyze
the data.
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2.2.6 Drug assay
The drug assay evaluated the drug content and uniformity of physical mixtures, HME
filaments, and FDM 3D printed tablets. Sample (25-50 mg) of the physical mixture, HME
filaments, and 3D printed tablets were dissolved in 20 mL methanol, then mixed using vortex to
help solubilize the sample in methanol. Samples were diluted ten times and then analyzed using
HPLC.
2.2.7 In-vitro drug release study
The in-vitro drug release profile of 3D printed tablets was evaluated using a United States
Pharmacopeia (USP) dissolution apparatus II (paddle) (Hanson Research Virtual Instruments
SR8 Plus, Los Angeles, CA). The dissolution medium was 900 mL 0.1 N HCL (pH 1.2) and was
maintained at 37± 0.5 ºC and 50 rpm. A sample volume of 2 mL was withdrawn using a
dissolution cannula topped with a filter tip of 10 µm for DISS 1000 (Thermo scientific) at time
points 0, 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 hours. The samples were replaced with a fresh dissolution
medium to maintain the total volume in the apparatus. Later the withdrawn samples were
analyzed using HPLC.
2.2.8 HPLC analysis
The samples of drug content and drug release were analyzed using the HPLC method
with The Waters HPLC-UV system (Waters Corporation, Milford, MA, USA). The column used
was a Luna 5u C18 column (5 microns, 150* 4.60 mm). The test conditions were set up: column
temperature 25 °C, flow rate 0.4 mL/min, injection volume 10 µL, and detection wavelength 267
nm. It was indicated in the literature that the best separation was achieved in the mobile phase
composed of methanol (a) and 1% acetic acid aqueous solution (b) in the ratio of 30:70 (v/v).
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[30]. The calibration curve is prepared using concentration (5, 10, 25, 50, and 100 µg/mL), R2 ~
0.9999.
2.2.9 Floating profile
The floating tablets profile was performed directly after the 3D printed tablet was created into
20 ml Glass Scintillation Vials using bottled water to test the floating duration. The duration of
time that the 3D printed tablet constantly remained on the surface was determined as the total floating
time.

14

CHAPTER III
RESULTS AND DISCUSSION
3.1 Formulation Composition
The characteristics and thermal properties of the polymers used are shown in Table 4.
HPC is a cellulose derivative with plasticity, hydrophobicity, hydrophilicity property, and low
Tg (depending on the moisture content). A high swell ability property makes it appropriate for
modified drug release kinetics. EC was used in this research to enhance the mechanical
properties of the filament. It possesses excellent thermal plasticity in some polymeric matrixes,
which means softening or fusing when heated up and hardening and turning rigid again when
cooled. HPMC-E5 is a swellable hydrophilic polymer that helps control a modified release
formulation. PEO N80 as a polymeric carrier. PEO has different grades, and the N80 grade is
one of the low grades with a molecular weight of 200,000 [38]. PEO N80 has a history of being
used for successful extended-release applications of osmotic pump technologies, gastroretentive
dosage forms (GRDF), hot-melt extruded products, hydrophilic matrices, and other drug delivery
systems. PEO N80 has a thermoplastic property and is highly crystalline with a low melting
temperature characteristic for hot melt extrusion; it was assumed to be a good choice for this
research [34].
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Table 4. The characteristics and thermal properties of the polymers.
The chemical name of the

Used in

Melting temperature (Tm)

Glass Transition

polymer

FDA

°C

Temperature (Tg)

approved

°C

drug
product
Ethylcellulose (EC) N.F.

Yes

240-255

130-133[39]

Yes

Amorphous

0 and 120 [40]

Yes

63- 67

-50[41]

Yes

Amorphous

-67.15[42]

Yes

Amorphous

154[41]

premium
Hydroxypropyl cellulose
(HPC-LF)

Polyethylene oxide (PEO
N80)
Polyethylene Glycol
(PEG1500)
HPMC E5

In this current research, the aim is to create a famotidine floating tablet using HME with
FDM 3D printing and the integrated role of polymers and excipients within the formulations to have
a longer time in the stomach.
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3.2 Hot-Melt Extrusion
All formulations were successfully extruded. The screw configuration consisted of four
conveying zones and three mixing zones. A 1.5 mm round die was used, and the diameter of the
extruded filaments was ~ 1.7. The increase in the diameter was since there was a swelling of the
filaments after leaving the die end, and it reached the desired 1.7 mm. The color of filaments
varied from one formulation composition and another, which was white to off-white in most
cases. For formulations with EC and PEO, which changed the color of the filaments to dark
yellow, This is possible because of the oxidation of EC in the formulation at high
temperature(Table 5). The screw speed was set at 100 rpm speed. The justification for using 7090 °C is to prevent building materials, stop sticking, and ensure smooth feeding to the following
zones. The extruded filaments were kept in plastic bags until further use. M17 extrusion
temperature parameter was distinct from the other formulations; the extrusion temperature was
150 °C, except the first zone was 25°C to have better flowability and prevent accumulation and
building up the material.
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Table 5. HME parameters for M1-M17 formulations.
Formulatio
n Code

Torqu
e
(Nm)

Die
Pressur
e (Bar)

M1
M2
M3
M4

1.2
1.3
1.7
2.9
4.9

25
30
28
1
13

M5

4.6

14

M6
M7
M8
M9

1.4
1.4
6.7
5.9

M10
M11

Extrusion
Temperatur
e
(°C)
120
120
120
160
120

First zone
temperatur
e
(°C)
70
70
70
160
90

Scre
w
speed
(rpm)
100
100
100
100
100

150

150

100

white

61
28
78
25

120
120
110
120

120
70
90
90

100
100
100
100

white
white
White
Milky
white

6.7
5.6

45
38

115
115

90
90

100
100

M12

4.8

45

115

90

100

M13

5.16

41

115

90

100

M14

3.6

53

150

150

100

M15

4.2

51

150

150

100

M16

3.0

50

150

150

100

M17

3.8

73

150

25

100

White
Dark
yellow
Dark
yellow
Dark
yellow
Light
yellow
Light
yellow
Light
yellow
Dark
yellow

18

Filament
color

Printabilit
y

white
White
White
White
Transparen
t

Failed
Failed
Failed
Failed
Failed
Diameter
> 1.7 mm
failed
Failed
Failed
Diameter
> 1.7 mm
Printable
Printable
Failed
Failed
Failed
printable
Printable
Printable

Formulation
code
M1

HME Filament

Formulation
code
M10

M2

M11

M3

M12

M4

M13

M5

M14

M6

M15

M7

M16

M8

M17

HME filament

M9

Figure 5: all the Formulations’ filaments extruded using a two screw HME.
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3.3 Fused deposition modeling 3D printing (FDM)
Printing was initiated by using PLA filaments. There was no significant difference in the
density between PLA and the filaments of the successful formulations. Therefore, the printing
was started with PLA first to review the design pattern and determine the desired tablet weight.
The first dimensions were (X20*Y20*Z10), and the weight of the PLA (480 mg) exceeded the
range needed (200-400 mg). Next, the dimensions were reduced to (X10*Y10*Z5), and the
weight of PLA was accepted (270 mg) (figure 6).

Figure 6: The Floating tablet design using PLA filaments through an FDM 3D printer.
M1-M9 and M12-M14 failed to print as the filaments were soft and were stuck in the
printer and could not pass through. The rationale behind that is the mechanical strength of HPC
polymer on the filament. Filaments became sticky inside the printer. Melted material was
incapable of pulling through the heater. An uneven flow of materials along the printer nozzle was
observed, including some sticking and pausing the printing process. Failure of printing for some
of the formulations was correlated to the high content of HPC and possibly moisture absorption,
which will affect the flexibility of the filaments.
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The filament diameter of M5 and M9 was more than 1.75 mm, which won't allow the
filament to go through the printer nozzle. Filaments from M10-M11 and M15-M17 were
printable (Table 6); the printing processing starts either the day after the extrusion or 2-days after
extrusion. The color of the tablets varied according to the filament color; however, they all
shared the same printing pattern, which was a line to make strong support for the hollow space
inside the tablet and reduce the gaps and reach the desired weight. The percent of the infill was
100% to prolong the floating tablet’s dissolution and increase the strength of the design.

21

Table 6. Successful formulations Printed tablets using FDM 3D printer
FORMULATION CODE

3D PRINTED TABLET

M10

M11

M15

M16

M17
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3.4 Weight variation
The 3D printed floating tablets for formulations M10 and M11 were weighed in an
analytical balance(Mettler Toledo , model# XSE204) ,and the results are displayed in Table 7.
The target weight was between 200-400 mg since famotidine strengths are 20 mg and 40 mg,
making our weight range more flexible. All of the printed tablets were within the desired weight
range.
Table 7. 3D printed floating tablet weight variations for M10 and M11
Formulation code

Average weight (mg)

RSD

M11

279.1

1.38

M10

293.7

1.48

3.5 Differential Scanning Calorimetry (DSC)
The analysis of the thermal properties of the drug, polymers, and excipients established a
connection between temperature and specific physical properties of the substances using the
melting point of the drug and glass transition temperature for polymers and other substances.
Famotidine thermograms showed an endothermic melting point peak at 164.76 °C. This
endothermic peak disappeared in the extruded filament and printed tablets, indicating complete
solubilization of famotidine in the polymeric carriers for all Five formulations studied (Figures 7,
8).

23

Figure 7. DSC thermogram of F10, 11, 13 for both filaments (F) and printed tablets (P),
Famotidine, HPMC-E5 , HPC-LF, EC.

Figure 8. DSC thermogram of F15, 16, 17 for both filaments (F) and printed tablets (P),
Famotidine, HPMC-E5, PEO N80.
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3.6 Drug content study
Formulations M10 and M11 were examined to analyze the famotidine content in the
tablets after to check whether the EC presence or absence influences the results. M10 with no EC
exhibited a higher but more variable drug content (Average DC = 99.2 %, RSD= 10.1) than M11
with 5% EC (Average= 62.2, SD=1.7).
3.7 in-vitro drug release study
The dissolution of tablets made with the M10 formulations were performed. (Figure 9).
Famotidine continued in M10 formulation floating in the media for 9 hours until fully dissolved.
That revealed that the 3D printing floating tablet design was successful for M10 towards
prolonging the floating and releasing the famotidine.
The release of M17 formulation was for 8 hours until fully dissolved. Resulted release
data were low despite the good floating profile. The assumption was that the PEO swelling
mechanism around the famotidine increased the duration of releasing famotidine from the dosage
form.

Average Drug release (%)

M10 Drug release
70
60
50
40
30
20
10
0
0

1

2

3

4
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7

8

9

(Hours)

Figure 9. The dissolution profile of 3D printed tablets for M10 in 0.1N HCL (pH 1.2) media,
apparatus II
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10

3.8 Floating analysis
Floating tests were examined successfully for printed tablets for formulations M10, M11,
and M17 (Figure 11 and 12, respectively). The floating test was performed in 20 mL cantillation
vial directly after the 3D printing and monitored every hour until either tablet sink or dissolved.
The vial's resulting floating profile showed that tablets on M10 and M11 floated for about 9
hours while M17 floated for about 8 hours. The floating profile results were confirmed within the
dissolution apparatus at the drug release experiment day. The observed results between the vial
and dissolution was consistent in the floating time for the formulations M10, M11, and M17
despite the presence of paddle in the dissolution apparatus, yet the floating matched the vial
floating time.

Figure 10. Floating test on M10 and M11 after 3D printing
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Figure 11. Dissolution of M17 to assess the drug release and the floating profile.
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CHAPTER IV
CONCLUSION
Famotidine formulation development for floating tablets using hot-melt extrusion with
FDM 3D-printing technology was examined and produced. The HME process was shown to
have the ability to develop some suitable filaments regarding the mechanical properties for
FDM-3D printing of floating tablets of famotidine through the printer for some successful
formulations. The Finding in the formulations with both HPC (different grades ) and HPMC E5
is hard to print because of the soft filament properties. Assumption of EC-containing
formulations may need to add anti-oxidation due to the oxidation of EC in high temperatures.
Five filaments (M10, M11, M15, M16, M17) out of seventeen were printable based on printing
trials. M10, M11, and M17 showed a good floating profile in both 20 ml vials and confirmed in
the dissolution apparatus. Drug release observations for floating tablets for both M10 and M17
were examined for 9 hours and 8 hours, respectively, until fully dissolved. Drug release and
floating were maintained for both M10 and M17. Finally, formulation optimization for floating
famotidine tablet needs to be performed.
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